160 related articles for article (PubMed ID: 28592183)
1. Vaginal film for prevention of HIV: using visual and tactile evaluations among potential users to inform product design.
Guthrie KM; Rohan L; Rosen RK; Vargas SE; Shaw JG; Katz D; Kojic EM; Ham AS; Friend D; Buckheit KW; Buckheit RW
Pharm Dev Technol; 2018 Mar; 23(3):311-314. PubMed ID: 28592183
[TBL] [Abstract][Full Text] [Related]
2. User-identified gel characteristics: a qualitative exploration of perceived product efficacy of topical vaginal microbicides.
Morrow KM; Underhill K; van den Berg JJ; Vargas S; Rosen RK; Katz DF
Arch Sex Behav; 2014 Oct; 43(7):1459-67. PubMed ID: 24452632
[TBL] [Abstract][Full Text] [Related]
3. The Role of Volume in the Perceptibility of Topical Vaginal Formulations: User Sensory Perceptions and Experiences of Heterosexual Couples During Vaginal Sex.
Guthrie KM; Fava JL; Vargas SE; Rosen RK; Shaw JG; Kojic EM; Ham AS; Rohan LC; Katz D; Panameño A; Colleran C; Friend DF; Buckheit KW; Buckheit RW
AIDS Res Hum Retroviruses; 2020 Dec; 36(12):1059-1070. PubMed ID: 32988214
[TBL] [Abstract][Full Text] [Related]
4. User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences.
Guthrie KM; Rosen RK; Vargas SE; Getz ML; Dawson L; Guillen M; Ramirez JJ; Baum MM; Vincent KL
PLoS One; 2018; 13(5):e0197269. PubMed ID: 29758049
[TBL] [Abstract][Full Text] [Related]
5. "Set it and forget it": women's perceptions and opinions of long-acting topical vaginal gels.
van den Berg JJ; Rosen RK; Bregman DE; Thompson LA; Jensen KM; Kiser PF; Katz DF; Buckheit K; Buckheit RW; Morrow KM
AIDS Behav; 2014 May; 18(5):862-70. PubMed ID: 24248674
[TBL] [Abstract][Full Text] [Related]
6. Meaning-making matters in product design: users' sensory perceptions and experience evaluations of long-acting vaginal gels and intravaginal rings.
Rosen RK; van den Berg JJ; Vargas SE; Senocak N; Shaw JG; Buckheit RW; Smith KA; Guthrie KM
Contraception; 2015 Dec; 92(6):596-601. PubMed ID: 26276246
[TBL] [Abstract][Full Text] [Related]
7. Perceptibility and the "Choice Experience": User Sensory Perceptions and Experiences Inform Vaginal Prevention Product Design.
Guthrie KM; Dunsiger S; Vargas SE; Fava JL; Shaw JG; Rosen RK; Kiser PF; Kojic EM; Friend DR; Katz DF
AIDS Res Hum Retroviruses; 2016; 32(10-11):1022-1030. PubMed ID: 26942455
[TBL] [Abstract][Full Text] [Related]
8. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties.
Morrow KM; Fava JL; Rosen RK; Vargas S; Shaw JG; Kojic EM; Kiser PF; Friend DR; Katz DF;
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):78-91. PubMed ID: 24180360
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398.
Grammen C; Van den Mooter G; Appeltans B; Michiels J; Crucitti T; Ariën KK; Augustyns K; Augustijns P; Brouwers J
Int J Pharm; 2014 Nov; 475(1-2):238-44. PubMed ID: 25175729
[TBL] [Abstract][Full Text] [Related]
10. Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
Hart CW; Joanis C; Hartmann M; Milford C; Smit J; Beksinska M; Rambally-Greener L; Pienaar J; Mabude Z; Butterworth GAM; Sokal D; Jenkins D
Eur J Contracept Reprod Health Care; 2019 Oct; 24(5):390-398. PubMed ID: 31517545
[No Abstract] [Full Text] [Related]
11. Preferred Physical Characteristics of Vaginal Film Microbicides for HIV Prevention in Pittsburgh Women.
Fan MD; Kramzer LF; Hillier SL; Chang JC; Meyn LA; Rohan LC
Arch Sex Behav; 2017 May; 46(4):1111-1119. PubMed ID: 27571742
[TBL] [Abstract][Full Text] [Related]
12. Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.
Woodsong C; Holt JD
Adv Drug Deliv Rev; 2015 Sep; 92():146-54. PubMed ID: 25703190
[TBL] [Abstract][Full Text] [Related]
13. Design aspects of vaginal applicators that influence acceptance among target users.
Bakke AJ; Zaveri T; Higgins MJ; Ziegler GR; Hayes JE
Sci Rep; 2021 May; 11(1):9802. PubMed ID: 33963262
[TBL] [Abstract][Full Text] [Related]
14. Qualitative exploration of intrinsic and extrinsic factors that influence acceptability of semisoft vaginal suppositories.
Zaveri T; Powell KA; Guthrie KM; Bakke AJ; Ziegler GR; Hayes JE
BMC Womens Health; 2018 Oct; 18(1):170. PubMed ID: 30342510
[TBL] [Abstract][Full Text] [Related]
15. The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.
Morrow K; Rosen R; Richter L; Emans A; Forbes A; Day J; Morar N; Maslankowski L; Profy AT; Kelly C; Abdool Karim SS; Mayer KH
J Womens Health (Larchmt); 2003 Sep; 12(7):655-66. PubMed ID: 14583106
[TBL] [Abstract][Full Text] [Related]
16. Microbicide preference among young women in California.
Holt BY; Morwitz VG; Ngo L; Harrison PF; Whaley KJ; Pettifor A; Nguyen AH
J Womens Health (Larchmt); 2006 Apr; 15(3):281-94. PubMed ID: 16620187
[TBL] [Abstract][Full Text] [Related]
17. Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities.
Hammett TM; Mason TH; Joanis CL; Foster SE; Harmon P; Robles RR; Finlinson HA; Feudo R; Vining-Bethea S; Jeter G; Mayer KH; Doherty-Iddings P; Seage GR
Sex Transm Dis; 2000 Feb; 27(2):119-26. PubMed ID: 10676980
[TBL] [Abstract][Full Text] [Related]
18. The slow evolution of microbicides for STD/HIV prevention.
Howes J; Bass M
J Gend Specif Med; 1999; 2(3):22-3. PubMed ID: 11252848
[No Abstract] [Full Text] [Related]
19. High-risk women's willingness to try a simulated vaginal microbicide: results from a pilot study.
Mosack KE; Weeks MR; Novick Sylla L; Abbott M
Women Health; 2005; 42(2):71-88. PubMed ID: 16537301
[TBL] [Abstract][Full Text] [Related]
20. Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.
Timur SS; Şahin A; Aytekin E; Öztürk N; Polat KH; Tezel N; Gürsoy RN; Çalış S
Pharm Dev Technol; 2018 Mar; 23(3):301-310. PubMed ID: 28503983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
